Interim clinical data of SynKIR™-310, a CD19-targeted KIR-CAR T therapy, showed no CRS, ICANS, or DLT in the first two dose levels, coupled with robust antitumor activity in patients with relapsed or refractory B-cell non-Hodgkin Lymphoma (B-NHL) Verismo also presenting…
The Clinical Trial Vanguard SynKIR-310 Shows 80% Response Rate With No Severe Toxicity in Lymphoma Trial Four out of five evaluable patients responded to SynKIR-310, and three of the six treated received it as outpatients. Those two numbers define what Verismo…
Becton, Dickinson and Company announced the U.S. commercial launch of the BD Liverty TIPS Stent Graft, advancing portal hypertension care by giving physicians greater flexibility to tailor treatment... Becton, Dickinson and Company announced the U.S commercial launch of the BD Liverty…
TradingView Grand Pharmaceutical Says Phase III Trial For CBT-001 Reaches Primary Clinical Endpoint
Physicians Weekly 6 Considerations for Managing Brain Metastases in Older Adults With NSCLC Given that older adults are underrepresented in clinical trials, an article in Frontiers in Oncology shared strategies for individualized decision-making for older adults with non-small cell lung cancer…
Elisabeth Heath discusses the FDA approval of capivasertib for PTEN-deficient metastatic hormone-sensitive prostate cancer, reviewing CAPItello-281 data in de novo patients randomized to capivasertib plus abiraterone versus abiraterone alone, both with ADT. The hazard ratio was approximately 0.8, with the control…
Nov 03, 2026, 19:00 ET SynKIR™-110 demonstrated faster tumor control with approximately 10-fold lower IFNγ and 30-fold lower TNFα and IL-2 production compared to CD28-based single-chain CAR T in preclinical models Preclinical in vivo data showed reduced exhaustion of tumor-infiltrating SynKIR™-110 T cells…
KIRYAT GAT, Israel, Oct. 27, 2026 (GLOBE NEWSWIRE) -- OPKO Biologics Ltd., an OPKO Health company (NASDAQ:OPK), today announced that the first participant has been dosed in a first-in-human Phase 1/2a clinical trial of OPK-8801001, an investigational, long acting human growth hormone receptor…
American Hospital Association A UVA Health scientist has developed an experimental drug that reversed paralysis and vision loss in a laboratory mouse model of multiple sclerosis (MS), offering a potential new therapy for a disease that currently has no cure.
AstraZeneca’s regulatory filings for a TAGRISSO and ORPATHYS combination have been accepted in Europe and Japan for a form of non-small cell lung cancer. The… AstraZeneca (LSE:AZN) said its filings for the TAGRISSO plus ORPATHYS regimen have been accepted…
Trial design, systematic reviews, medical statistics, and guideline updates.
An article joins this feed when it matches these terms. Each one is also a search of its own.